Transforming growth factor-β and breast cancer: Lessons learned from genetically altered mouse models

[1]  M. Kretzschmar,et al.  Transforming growth factor-β and breast cancer: Transforming growth factor-β/SMAD signaling defects and cancer , 2000, Breast Cancer Research.

[2]  W. Dupont,et al.  Transforming Growth Factor-β and Breast Cancer Risk in Women With Mammary Epithelial Hyperplasia. , 1999, Journal of the National Cancer Institute.

[3]  P S Gartside,et al.  Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. , 1999, Cancer research.

[4]  X. F. Wang,et al.  Targeted Disruption of Smad3 Reveals an Essential Role in Transforming Growth Factor β-Mediated Signal Transduction , 1999, Molecular and Cellular Biology.

[5]  H. Moses,et al.  Overexpression of a kinase-deficient transforming growth factor-beta type II receptor in mouse mammary stroma results in increased epithelial branching. , 1999, Molecular biology of the cell.

[6]  T. Doetschman,et al.  Strain dependency of TGFβ1 function during embryogenesis , 1999 .

[7]  A. Roberts,et al.  Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF‐β , 1999, The EMBO journal.

[8]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[9]  H. Beug,et al.  TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis , 1998, Current Biology.

[10]  J. Graff,et al.  Smad3 Mutant Mice Develop Metastatic Colorectal Cancer , 1998, Cell.

[11]  C. Deng,et al.  Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Steven Dyson,et al.  The Interpretation of Position in a Morphogen Gradient as Revealed by Occupancy of Activin Receptors , 1998, Cell.

[13]  Hiroyuki Miyoshi,et al.  Intestinal Tumorigenesis in Compound Mutant Mice of both Dpc4(Smad4) and Apc Genes , 1998, Cell.

[14]  Y. Nagamachi,et al.  Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-beta type II receptor gene in sporadic human breast cancers. , 1998, Oncology reports.

[15]  R. Derynck,et al.  Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[16]  L. Wakefield,et al.  Transgenic Mice Overexpressing a Dominant-negative Mutant Type II Transforming Growth Factor β Receptor Show Enhanced Tumorigenesis in the Mammary Gland and Lung in Response to the Carcinogen 7,12-Dimethylbenz-[a]-anthracene , 1997 .

[17]  L. Hennighausen,et al.  Inhibins and activins regulate mammary epithelial cell differentiation through mesenchymal-epithelial interactions. , 1997, Development.

[18]  K. Kinzler,et al.  Frequency of Smad gene mutations in human cancers. , 1997, Cancer research.

[19]  G. Boivin,et al.  TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. , 1997, Development.

[20]  M. Taketo,et al.  TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. , 1996, Developmental biology.

[21]  M. Yin,et al.  Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Ferguson,et al.  Transforming growth factor–β3 is required for secondary palate fusion , 1995, Nature Genetics.

[23]  R. Coffey,et al.  Mammary tumor suppression by transforming growth factor beta 1 transgene expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Hennighausen,et al.  Ectopic TGF beta 1 expression in the secretory mammary epithelium induces early senescence of the epithelial stem cell population. , 1995, Developmental biology.

[25]  B. Hogan,et al.  Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. , 1993, Genes & development.

[26]  A. Geiser,et al.  Targeting expression of a transforming growth factor beta 1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. , 1993, The EMBO journal.

[27]  M. Sporn,et al.  Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[29]  K. Flanders,et al.  Regulated expression and growth inhibitory effects of transforming growth factor-beta isoforms in mouse mammary gland development. , 1991, Development.

[30]  S. Robinson,et al.  TGF-beta 1-induced inhibition of mouse mammary ductal growth: developmental specificity and characterization. , 1989, Developmental biology.

[31]  Pierce Gb,et al.  Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. , 1988 .

[32]  Thomas H. Maugh,et al.  Breast Cancer Research , 1978, British Journal of Cancer.

[33]  G. Boivin,et al.  TGF β 2 knockout mice have multiple developmental defects that are non-overlapping with other TGF β knockout phenotypes , 1997 .

[34]  M. Sporn,et al.  Transforming growth factor-beta s in mammary tumorigenesis: promoters or antipromoters? , 1995, Progress in clinical and biological research.

[35]  G. B. Pierce,et al.  Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. , 1988, Cancer research.